• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Avelox (moxifloxacin hydrochloride)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – October 2011

 

Summary View

 

Avelox (moxifloxacin hydrochloride) Tablets and IV

 

WARNINGS AND PRECAUTIONS

Central Nervous System Effects/ Disorders
  • Convulsions and increased intracranial pressure (including pseudotumor cerebri) have been reported...